A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(3 sites)

Dominican Republic

GSK Investigational Site, Salvaleón de Higüey, La Altagracia Province

GSK Investigational Site, Constanza

GSK Investigational Site, Santo Domingo Oeste